SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (459)2/17/2004 10:34:19 AM
From: tuck   of 625
 
From Briefing.com this morning:

>>AG Edwards downgrades Cambridge Antibody Technology to Hold from Buy as the firm believes the internal pipeline lacks the firepower to drive significant outperformance. What struck the firm: Data from the phase 1/2 trial of CAT-192 was sufficiently ambiguous that "no definitive conclusions..." could be drawn. The firm believes investors should take a pause and wait for positive developments in both the conflict with Abbott as well as an enhanced internal pipeline.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News